Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Papadopoulos

Showing results (221-230 of 288) with videos related to

Pageof 29
Sort By:
Cureus|April 13, 2022
SARS-CoV-2 Vaccination Coverage and Key Public Health Indicators May Explain Disparities in COVID-19 Country-Specific Case Fatality Rate Within European Economic AreaVasileios P Papadopoulos, Anatoli Emmanouilidou, Marios Yerou, et al.
Cancer Chemotherapy and Pharmacology|June 22, 2018
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancerAmita Patnaik, Michael Gordon, Frank Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2014
Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumorsToshio Shimizu, Patricia M LoRusso, Kyri P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology|December 4, 2013
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumorsAnthony W Tolcher, Wendi V Rodrigueza, Drew W Rasco, et al.
Nature Medicine|April 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysisToni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Journal of Clinical Pharmacology|May 16, 2014
Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmationMark Stroh, Jennifer Talaty, Punam Sandhu, et al.
The Journal of Clinical Investigation|December 19, 2002
Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targetingValérie Dutoit, Robert N Taub, Kyriakos P Papadopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2014
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumorsA W Tolcher, J C Bendell, K P Papadopoulos, et al.
Journal of Clinical Pharmacology|December 8, 2016
Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple MyelomaYing Ou, Sameer Doshi, Anh Nguyen, et al.
Cancer Chemotherapy and Pharmacology|August 11, 2012
A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancerRichard M Lush, Amita Patnaik, Daniel Sullivan, et al.
Pageof 29

Showing results (221-230 of 288) with videos related to

Sort By:
Pageof 29
Cureus|April 13, 2022
SARS-CoV-2 Vaccination Coverage and Key Public Health Indicators May Explain Disparities in COVID-19 Country-Specific Case Fatality Rate Within European Economic AreaVasileios P Papadopoulos, Anatoli Emmanouilidou, Marios Yerou, et al.
Cancer Chemotherapy and Pharmacology|June 22, 2018
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancerAmita Patnaik, Michael Gordon, Frank Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2014
Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumorsToshio Shimizu, Patricia M LoRusso, Kyri P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology|December 4, 2013
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumorsAnthony W Tolcher, Wendi V Rodrigueza, Drew W Rasco, et al.
Nature Medicine|April 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysisToni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Journal of Clinical Pharmacology|May 16, 2014
Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmationMark Stroh, Jennifer Talaty, Punam Sandhu, et al.
The Journal of Clinical Investigation|December 19, 2002
Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targetingValérie Dutoit, Robert N Taub, Kyriakos P Papadopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2014
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumorsA W Tolcher, J C Bendell, K P Papadopoulos, et al.
Journal of Clinical Pharmacology|December 8, 2016
Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple MyelomaYing Ou, Sameer Doshi, Anh Nguyen, et al.
Cancer Chemotherapy and Pharmacology|August 11, 2012
A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancerRichard M Lush, Amita Patnaik, Daniel Sullivan, et al.
Pageof 29